Pricing
  1. US-listed companies
  2. U.S. Stem Cell, Inc.
  3. Financials
  4. Stock-based compensation

U.S. Stem Cell, Inc.【USRM】

Market cap
$64.15K
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Dec 31, 20220-30.94%
Dec 31, 20211-20.71%
Dec 31, 20201-42.84%
Dec 31, 20181+90.23%
Dec 31, 20171+57.43%
Dec 31, 20160-64.42%
Dec 31, 20151+114.32%
Dec 31, 20141-94.66%
Dec 31, 201310+1.26%
Dec 31, 201210+0.78%
Dec 31, 201110

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)